Eli Lilly and Company(LLY) - Stock detail

Eli Lilly and Company

US
LLY
Eli Lilly and Company(Listing date: 07/09/1970)

Eli Lilly and Company was incorporated in Indiana in 1901, with its predecessor being a pharmaceutical manufacturing enterprise founded by Colonel Eli Lilly in Indianapolis, Indiana in 1876. The company develops, manufactures and markets important pharmaceutical products. Its mission is to combine "Caring" and "Discovery" to create better lives for people around the world.

AI Rating

Rating methodology
Latest close (chg%)927.03+2.55%
Buy price
931.00
Target price1095.00
Sell price875.00
P/E TTM47.85
P/E91.43
Confidence70%
Risk score60/100
AI Summary
The decision is based on a fundamental inflection point created by Foundayo's Phase III cardiovascular data, which de-risks the regulatory pathway and expands the total addressable market into Type 2 diabetes. A scaled entry strategy is recommended to manage high valuation (Forward P/E 91.43) and volatility risks.

Alpha Score

0-10
  • Trend（Score 4/10）

    LLY presents a conflict between a damaged medium-term downtrend and emerging short-term bullish signals, currently at a technical inflection point with a recommendation to Hold and watch key support/resistance levels.

  • Valuation（Score 2/10）

    Valuation metrics indicate the stock is trading at a significant premium with very high multiples (P/E of 47.85, P/B of 41.51, Forward P/E of 91.43), reflecting high growth expectations. Based on traditional metrics, LLY appears significantly overvalued, with valuation entirely dependent on sustained explosive growth.

  • Financial strength（Score 5/10）
    Financial health shows both strength and significant leverage, with adequate short-term liquidity (Current Ratio 1.58, Quick Ratio 1.19) but high debt levels (Debt-to-Asset Ratio 76.41%) creating a highly leveraged capital structure that increases financial risk.
  • Profitability（Score 10/10）
    Eli Lilly is demonstrating exceptional and accelerating profitability with explosive revenue growth (44.70% YoY to $65.18B in 2025) and staggering net income growth (94.90% increase to $20.64B). Margins are extremely high (Gross Margin 83.04%, Net Margin 31.67%) and return metrics outstanding (ROE 101.16%, ROA 21.59%).
  • Sentiment（Score 9/10）
    Eli Lilly's Foundayo launch and positive Phase III cardiovascular data significantly de-risk the drug, expand its market into Type 2 diabetes, and strengthen the company's long-term growth outlook, justifying a bullish stance.
Latest price
$927.03+2.55%
Market cap875.88B
P/E TTM47.85
P/E91.43
Volume3.24M
Turnover3B